153 related articles for article (PubMed ID: 38452923)
1. Treating liver cancer through arginine depletion.
Prasad YR; Anakha J; Pande AH
Drug Discov Today; 2024 Apr; 29(4):103940. PubMed ID: 38452923
[TBL] [Abstract][Full Text] [Related]
2. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma.
Cheng PN; Leung YC; Lo WH; Tsui SM; Lam KC
Cancer Lett; 2005 Jun; 224(1):67-80. PubMed ID: 15911102
[TBL] [Abstract][Full Text] [Related]
3. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
[TBL] [Abstract][Full Text] [Related]
4. A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.
Chan SL; Cheng PNM; Liu AM; Chan LL; Li L; Chu CM; Chong CCN; Lau YM; Yeo W; Ng KKC; Yu SCH; Mok TSK; Chan AWH
Invest New Drugs; 2021 Oct; 39(5):1375-1382. PubMed ID: 33856599
[TBL] [Abstract][Full Text] [Related]
5. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Kuo MT; Savaraj N; Feun LG
Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
[TBL] [Abstract][Full Text] [Related]
6. Arginine deprivation in cancer therapy.
Feun LG; Kuo MT; Savaraj N
Curr Opin Clin Nutr Metab Care; 2015 Jan; 18(1):78-82. PubMed ID: 25474015
[TBL] [Abstract][Full Text] [Related]
7. Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1.
Glazer ES; Kaluarachchi WD; Massey KL; Zhu C; Curley SA
Surgery; 2010 Aug; 148(2):310-8. PubMed ID: 20466402
[TBL] [Abstract][Full Text] [Related]
8. Human arginase I: a potential broad-spectrum anti-cancer agent.
Anakha J; Prasad YR; Sharma N; Pande AH
3 Biotech; 2023 May; 13(5):159. PubMed ID: 37152001
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma.
Yau T; Cheng PN; Chan P; Chan W; Chen L; Yuen J; Pang R; Fan ST; Poon RT
Invest New Drugs; 2013 Feb; 31(1):99-107. PubMed ID: 22426640
[TBL] [Abstract][Full Text] [Related]
11. Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.
Kumari N; Bansal S
Cancer Chemother Pharmacol; 2021 Oct; 88(4):565-594. PubMed ID: 34309734
[TBL] [Abstract][Full Text] [Related]
12. A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer.
Chung SF; Kim CF; Tam SY; Choi MC; So PK; Wong KY; Leung YC; Lo WH
Appl Microbiol Biotechnol; 2020 May; 104(9):3921-3934. PubMed ID: 32144472
[TBL] [Abstract][Full Text] [Related]
13. Changes in arginase isoenzymes pattern in human hepatocellular carcinoma.
Chrzanowska A; Krawczyk M; Barańczyk-Kuźma A
Biochem Biophys Res Commun; 2008 Dec; 377(2):337-340. PubMed ID: 18831962
[TBL] [Abstract][Full Text] [Related]
14. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
[TBL] [Abstract][Full Text] [Related]
15. [Role of arginase-1 expression in distinguishing hepatocellular carcinoma from non-hepatocellular tumors].
Sang W; Gulinar A; Wang CH; Sheng WQ; Maiweilidan Y; Zhang W
Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):538-42. PubMed ID: 24246920
[TBL] [Abstract][Full Text] [Related]
16. Human recombinant arginase I [HuArgI (Co)-PEG5000]-induced arginine depletion inhibits ovarian cancer cell adhesion and migration through autophagy-mediated inhibition of RhoA.
El-Mais N; Fakhoury I; Abdellatef S; Abi-Habib R; El-Sibai M
J Ovarian Res; 2021 Jan; 14(1):13. PubMed ID: 33423701
[TBL] [Abstract][Full Text] [Related]
17. Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines.
Stone EM; Glazer ES; Chantranupong L; Cherukuri P; Breece RM; Tierney DL; Curley SA; Iverson BL; Georgiou G
ACS Chem Biol; 2010 Mar; 5(3):333-42. PubMed ID: 20050660
[TBL] [Abstract][Full Text] [Related]
18. Liver arginase activity and urea metabolism in beef heifers fed urea diets and abomasally infused with arginine and(or) ammonium acetate.
Koenig JM; Bradley NW; Boling JA
J Anim Sci; 1982 Feb; 54(2):426-33. PubMed ID: 7076598
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion.
Leonard W; Dufait I; Schwarze JK; Law K; Engels B; Jiang H; Van den Berge D; Gevaert T; Storme G; Verovski V; Breckpot K; De Ridder M
Radiother Oncol; 2016 May; 119(2):291-9. PubMed ID: 26874542
[TBL] [Abstract][Full Text] [Related]
20. Arginase-induced cell death pathways and metabolic changes in cancer cells are not altered by insulin.
Chew HY; Cvetkovic G; Tepic S; Wells JW
Sci Rep; 2024 Feb; 14(1):4112. PubMed ID: 38374190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
